Keyphrases
Confidence Interval
100%
Phase II Trial
100%
Hazard Ratio
100%
Unresectable Hepatocellular Carcinoma
100%
Novel Combinations
100%
Combination Strategy
100%
Comparative Efficacy
100%
Network Metanalysis
100%
Overall Survival
33%
Progression-free Survival
33%
Embase
22%
Risk of Death
22%
Sorafenib
22%
Lenvatinib
22%
Atezolizumab Plus Bevacizumab
22%
Donafenib
22%
Placebo
11%
High Risk
11%
Randomized Controlled Trial
11%
MEDLINE
11%
Adverse Events
11%
Pathway Inhibitors
11%
Risk Reduction
11%
Vascular Endothelial Growth Factor
11%
Standard of Care
11%
Cochrane Library
11%
Multivariable
11%
Cabozantinib
11%
Nivolumab
11%
Tyrosine Kinase Inhibitor
11%
Literature Search
11%
Multiple Regression Model
11%
Prospero
11%
Fixed Effects
11%
Programmed Death-ligand 1 (PD-L1)
11%
Immune Checkpoint Inhibitors
11%
Locoregional Therapy
11%
Duplicate Removal
11%
Atezolizumab
11%
Growth Factor Pathway
11%
Text Reviews
11%
Frequentist Network Meta-analysis
11%
Durvalumab
11%
Sintilimab
11%
IBI305
11%
Tremelimumab
11%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Overall Survival
100%
Progression Free Survival
100%
Atezolizumab
100%
Sorafenib
66%
Bevacizumab
66%
Lenvatinib
66%
Placebo
33%
Randomized Controlled Trial
33%
Adverse Event
33%
Vasculotropin
33%
Protein Tyrosine Kinase Inhibitor
33%
Programmed Cell Death
33%
Nivolumab
33%
Immune Checkpoint Inhibitor
33%
Cabozantinib
33%
Durvalumab
33%
Tremelimumab
33%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Hazard Ratio
100%
Overall Survival
33%
Progression Free Survival
33%
Atezolizumab
33%
Sorafenib
22%
Bevacizumab
22%
Lenvatinib
22%
Programmed Cell Death
11%
Placebo
11%
Randomized Controlled Trial
11%
Adverse Event
11%
Vasculotropin
11%
Systematic Review
11%
Nivolumab
11%
Cabozantinib
11%
Tyrosine-Kinase Inhibitor
11%
Meta-Regression
11%
Network Meta-Analysis
11%
Regional Perfusion
11%
Immune Checkpoint Inhibitor
11%
Durvalumab
11%
Ticilimumab
11%
Agricultural and Biological Sciences
Confidence Interval
100%
Bevacizumab
22%
Placebo
11%
Meta-Analysis
11%
Systematic Review
11%
Vascular Endothelial Growth Factor
11%
Receptor Tyrosine Kinase
11%
Tremelimumab
11%
Programmed Cell Death 1
11%
Immunity
11%